Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
19 September 2024 - 6:05AM
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN),
a clinical-stage precision oncology company focused on the
discovery and development of next-generation small molecule kinase
inhibitors, today announced details for the updated ELVN-001 Phase
1a data, which was selected for an oral presentation at the
upcoming European Society of Hematology International Chronic
Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman
Conference taking place September 27-29 in Prague, Czech Republic.
ELVN-001 is a potent, highly selective, potentially
best-in-class small molecule kinase inhibitor designed to
specifically target the BCR-ABL gene fusion, the oncogenic driver
for patients with chronic myeloid leukemia (CML).
Details of the oral presentation are as
follows:Title: Preliminary safety and efficacy of
ELVN-001, a selective active site inhibitor of BCR::ABL1 in
CMLPresenter: Fabian Lang, MD, Goethe University
Hospital Session: Scientific Session 5: New drugs
and combinationsSession Date/Time: Saturday,
September 28, 2024, 3:00 - 4:20 p.m. CEST Presentation
Time: 3:35 - 3:50 p.m. CEST / 9:35 - 9:50 a.m. ET
A copy of the presentation will be available by visiting the
“Program Presentations & Publications” section of the Company’s
website at www.enliventherapeutics.com.
About Enliven TherapeuticsEnliven is a
clinical-stage biopharmaceutical company focused on the discovery
and development of small molecule inhibitors to help people with
cancer not only live longer, but live better. Enliven aims to
address existing and emerging unmet needs with a precision oncology
approach that improves survival and enhances overall well-being.
Enliven’s discovery process combines deep insights in clinically
validated biological targets and differentiated chemistry to design
potentially first-in-class or best-in-class therapies. Enliven is
based in Boulder, Colorado.
ContactInvestorsir@enliventherapeutics.com
Mediamedia@enliventherapeutics.com
Enliven Therapeutics (NASDAQ:ELVN)
Historical Stock Chart
From Oct 2024 to Nov 2024
Enliven Therapeutics (NASDAQ:ELVN)
Historical Stock Chart
From Nov 2023 to Nov 2024